Shots: LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals […]
Shots: Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close […]
Shots: The P-I/II TRIDENT-1 study evaluates repotrectinib in NTRK-positive TKI-naïve & pretreated advanced solid tumors. The early P-II data use an Aug 26, 2021 cutoff […]
In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates […]
Shots: ImmixBio to assess the safety, tolerability, and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors […]
In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) […]
Shots: The sBLA submission is based on results from a P-II study evaluating the efficacy & safety of tislelizumab (200 mg, IV, q3w) as monothx […]
Shots: The collaboration will evaluate Fusion’s FPI-1434 + Merck’s Keytruda in patients with solid tumors expressing IGF-1R. Fusion will sponsor the study and Merck will […]
Shots: The approval is based on the P-III NAVIGATE trial in adult and adolescent patients and P- I/II pediatric SCOUT trial involves assessing Vitrakvi for […]
The 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density and binding affinity for solid […]
Shots: Atara to receive $60M upfront and ~$610M as development, regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf […]
Shots: The approval is based on integrated analysis including data from 74 people with LA/ m-NTRK fusion-positive solid tumors (14 tumor types) & 161 people […]
Copyright © 2024 | WordPress Theme by MH Themes
